Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 1;42(25):2955-2960.
doi: 10.1200/JCO.23.02717. Epub 2024 Jun 6.

Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials

Damon R Reed  1   2 , Asmin Tulpule  1 , Jonathan Metts  3 , Matteo Trucco  4 , Mark Robertson-Tessi  5 , Tara J O'Donohue  1 , Fiorella Iglesias-Cardenas  1 , Michael S Isakoff  6 , Audrey Mauguen  7 , Neerav Shukla  1 , Filemon S Dela Cruz  1 , William Tap  2 , Alex Kentsis  1 , Carol D Morris  8 , Meera Hameed  9 , Joshua N Honeyman  8 , Gerald G Behr  10 , Maria Luisa Sulis  1 , Michael V Ortiz  1 , Emily Slotkin  1
Affiliations

Pediatric Leukemia Roadmaps Are a Guide for Positive Metastatic Bone Sarcoma Trials

Damon R Reed et al. J Clin Oncol. .

Abstract

ALL cures require many MRD therapies. This strategy should drive experiments and trials in metastatic bone sarcomas.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST DISCLOSURES

DRR reports personal fees for Data Safety Monitoring Committee roles with Springworks and Eisai outside the submitted work.

FDC receives institutional support from Eisai and Y-mAbs therapeutics

AK is a consultant for Novartis, Rgenta, Blueprint, and Syndax.

MO acknowledges current salary and research support from the Rally Foundation for Childhood Cancer Research, Infinite Love for Kids Fighting Cancer, The Jed Ian Taxel Foundation for Rare Cancer Research, Handstand Walk for Kids, the Serra Family and the Bianco Family Foundation, Team Caroline, and the NCI via U01 CA263967; MO has received institutional research support for clinical trials from Chugai, Amgen, Karyopharm, and Bayer.

TJO is employed at Amgen at the time of this submission but not during the writing of the manuscript

JNH spouse is employed by AstraZeneca

Figures

Figure 1:
Figure 1:. Current Metastatic Bone Sarcoma Trial Metrics in Context of Acute Lymphoblastic Leukemia Trials.
A: 5-year overall survival (OS) outcomes for acute lymphoblastic leukemia (ALL). The 1970’s dates are in era of BFM protocol 1 trials. H0 denotes current metastatic sarcoma (MBS) OS outcomes and + the threshold 5-year OS result for a positive trial. B: Net improvements in survival by ALL trial era showing that only early era trials are able to meet the absolute difference outcome detectable with current power required on recent MBS trials. C: Numbers of patients with ALL accrued on trials by era (n) with MBS trials enrolling approximately 300 patients per phase 3 trial (line). D: Survival improvement detectable per patient enrolled (figure 1B/figure 1A). ALL trials have never detected a per patient absolute survival difference as large as powered in MBS trials. (Panel A adapted from Mullighan, Hunger)
See this image and copyright information in PMC

References

    1. Hustu HO, Pinkel D, Pratt CB: Treatment of clinically localized Ewing’s sarcoma with radiotherapy and combination chemotherapy. Cancer 30:1522–7, 1972 - PubMed
    1. Link MP, Goorin AM, Miser AW, et al. : The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. The New England journal of medicine 314:1600–6, 1986 - PubMed
    1. Grier HE, Krailo MD, Tarbell NJ, et al. : Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. The New England journal of medicine 348:694–701, 2003 - PubMed
    1. Ebb D, Meyers P, Grier H, et al. : Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children’s oncology group. J Clin Oncol 30:2545–51, 2012 - PMC - PubMed
    1. Womer RB, West DC, Krailo MD, et al. : Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 30:4148–54, 2012 - PMC - PubMed